Press Release Details

Colfax Reports Third Quarter 2008 Financial Results

November 5, 2008

RICHMOND, Va., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Colfax Corporation (NYSE: CFX), a global leader in engineered fluid handling products and systems, today announced financial results for the third quarter ended September 26, 2008. On a year-over-year basis, highlights for the quarter and the first nine months of 2008 include:

(Logo: http://www.newscom.com/cgi-bin/prnh/20080508/DC21739LOGO )

Third quarter of 2008 (all comparisons versus the third quarter of 2007, unless otherwise noted)

    -- Net income of $13.7 million (31 cents per share - basic and diluted);
       Adjusted net income (as defined below) of $12.1 million (28 cents per
       share), an increase of 34.4%
    -- Net sales of $153.5 million, an increase of 22.4%; Organic sales growth
       (as defined below) of 14.3%
    -- Operating income of $20.9 million; Adjusted operating income (as
       defined below) of $20.3 million, an increase of 21.5%
    -- EBITDA (as defined below) of $24.6 million; Adjusted EBITDA (as defined
       below) of $24.0 million, an increase of 18.6%
    -- Third quarter orders of $173.8 million, an increase of 13.2%; Organic
       order growth (as defined below) of 5.7%
    -- Backlog of $383.1 million at period end


Year-to-date 2008 (all comparisons versus the year-to-date 2007, unless otherwise noted)

    -- Net loss of $10.9 million (43 cents per share - basic and diluted);
       Adjusted net income (as defined below) of $36.2 million (82 cents per
       share), an increase of 40.6%
    -- Net sales of $445.5 million, an increase of 22.9%; Organic sales growth
       (as defined below) of 11.8%
    -- Operating loss of $5.0 million; Adjusted operating income (as defined
       below) of $62.2 million, an increase of 29.5%
    -- EBITDA (as defined below) of $6.3 million; Adjusted EBITDA (as defined
       below) of $73.5 million, an increase of 24.2%
    -- Record orders for the nine month period of $542.9 million, an increase
       of 27.7%; Organic order growth (as defined below) of 15.7%


Adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth are not financial measures calculated in accordance with generally accepted accounting principles in the U.S. ("GAAP"). See below for a description of the measures' usefulness and a reconciliation of these measures to their most directly comparable GAAP financial measures.

"We are pleased with our third quarter performance," said John Young, President and CEO of Colfax Corporation. "We experienced organic sales growth across all of our end markets, most notably in commercial marine and power generation. With our recent order activity and current backlog, we are on target to meet our low double-digit organic sales growth goal for the year and expect to have a strong fourth quarter. Longer term, we believe we are well positioned as we enter 2009 with a diverse backlog and a strong balance sheet. The activity levels in our end markets remain sound; however, we're closely monitoring the impact of the recent economic uncertainty on our businesses."

The Company also announced today that its board of directors has authorized the repurchase of up to $20 million of the Company's common stock on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company's management based on its evaluation of market conditions and other factors. The repurchase program will be funded using the Company's working capital. The Company has approximately 44 million shares outstanding.

Non-GAAP Financial Measures

Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth. Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense cost (income) and asbestos coverage litigation expense, certain legacy legal charges, certain due diligence costs, as well as one time initial public offering-related costs. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of 34%. Adjusted net income per share assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Organic sales growth and organic order growth exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.

Conference Call and Webcast

Colfax will host a conference call to provide details about its results and business strategy on Wednesday, November 5, 2008 at 8:00 a.m. EST. The call will be open to the public through 719-325-4906 or 877-440-5807 and webcast via Colfax's website at http://www.colfaxcorp.com under the "Investor Relations" section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call. In addition, a replay of this call will be available until approximately November 20, 2008. The replay number in the U.S. is 888-203-1112 and internationally it is 719-457-0820, and the access code is 9343586.

About Colfax Corporation

Colfax Corporation is a global leader in critical fluid-handling solutions, including the manufacture of positive displacement industrial pumps and valves used in global oil & gas, power generation, marine, naval and a variety of other industrial applications. Key product brands include Allweiler, Fairmount Automation, Houttuin, Imo, LSC, Portland Valve, Tushaco, Warren and Zenith. Colfax is traded on the NYSE under the ticker "CFX." Additional information about Colfax's products, businesses and practices is available at www.colfaxcorp.com

CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, including forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Registration Statement on Form S-1 under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of this date. Colfax disclaims any duty to update the information herein.



                              Colfax Corporation
                Condensed Consolidated Statement of Operations
                (amounts in thousands, except per share data)
                                 (unaudited)


                                       Three Months Ended  Nine Months Ended
                                      September September September September
                                       26, 2008  28, 2007  26, 2008  28, 2007

    Net sales                          $153,461  $125,361  $445,543  $362,602
    Cost of sales                        98,983    80,849   286,110   236,226

    Gross profit                         54,478    44,512   159,433   126,376
    Initial public offering related
     costs                                    -         -    57,017         -
    Selling, general and
     administrative expenses             33,233    26,761    97,516    75,277
    Research and development expenses     1,478     1,005     4,430     3,075
    Asbestos liability and defense
     (income) costs                      (6,312)  (30,285)   (6,749)  (32,032)
    Asbestos coverage litigation
     expenses                             5,148     2,387    12,257     8,318

    Operating income (loss)              20,931    44,644    (5,038)   71,738
    Interest expense                      1,951     5,200     9,684    14,416

    Income (loss) before income taxes    18,980    39,444   (14,722)   57,322
    Provision (benefit) for income
     taxes                                5,329    14,433    (3,772)   21,432

    Net income (loss)                   $13,651   $25,011  $(10,950)  $35,890

    Net income (loss) available to
     common shareholders per share-
     basic and diluted                    $0.31     $1.14    $(0.43)    $1.02



                              Colfax Corporation
            Reconciliation of GAAP to non-GAAP Financial Measures
                (amounts in thousands, except per share data)
                                 (unaudited)


                                  Three Months Ended       Nine Months Ended
                                 September   September   September   September
                                  26, 2008    28, 2007    26, 2008    28, 2007

    EBITDA
    Net income (loss)             $13,651     $25,011    $(10,950)    $35,890

    Interest expense                1,951       5,200       9,684      14,416
    Provision (benefit) for
     income taxes                   5,329      14,433      (3,772)     21,432
    Depreciation and
     amortization                   3,695       3,522      11,345      11,205

    EBITDA                        $24,626     $48,166      $6,307     $82,943
    EBITDA margin                    16.0%       38.4%        1.4%       22.9%

    Adjusted EBITDA
    Net income (loss)             $13,651     $25,011    $(10,950)    $35,890

    Interest expense                1,951       5,200       9,684      14,416
    Provision (benefit) for
     income taxes                   5,329      14,433      (3,772)     21,432
    Depreciation and
     amortization                   3,695       3,522      11,345      11,205
    IPO-related costs                   -           -      57,017           -
    Legacy legal adjustment             -           -       4,131           -
    Due diligence costs               582           -         582           -
    Asbestos liability and
     defense (income) costs        (6,312)    (30,285)     (6,749)    (32,032)
    Asbestos coverage
     litigation expense             5,148       2,387      12,257       8,318

    Adjusted EBITDA               $24,044     $20,268     $73,545     $59,229
    Adjusted EBITDA margin           15.7%       16.2%       16.5%       16.3%

    Adjusted Net Income and
     Adjusted Earnings per
     Share
    Net income (loss)             $13,651     $25,011    $(10,950)    $35,890
    IPO-related costs                   -           -      57,017           -
    Legacy legal adjustment             -           -       4,131           -
    Due diligence costs               582           -         582           -
    Asbestos liability and
     defense (income) costs        (6,312)    (30,285)     (6,749)    (32,032)
    Asbestos coverage
     litigation expense             5,148       2,387      12,257       8,318
    Interest adjustment to
     effect IPO at beginning
     of period                          -       2,143       2,302       5,393
    Tax adjustment to 34%
     effective rate                  (926)      9,779     (22,410)      8,172

    Adjusted net income           $12,143      $9,035     $36,180     $25,741
    Adjusted net income margin        7.9%        7.2%        8.1%        7.1%

    Shares outstanding at
     closing of IPO            44,006,026  44,006,026  44,006,026  44,006,026
    Adjusted net income per
     share                          $0.28       $0.21       $0.82       $0.58

    Net income (loss) per
     share-basic and diluted
     in accordance with GAAP        $0.31       $1.14      $(0.43)      $1.02

    Adjusted Operating Income
    Operating income (loss)       $20,931     $44,644     $(5,038)    $71,738
    IPO-related costs                   -           -      57,017           -
    Legacy legal adjustment             -           -       4,131           -
    Due diligence costs               582           -         582           -
    Asbestos liability and
     defense (income) costs        (6,312)    (30,285)     (6,749)    (32,032)
    Asbestos coverage
     litigation expense             5,148       2,387      12,257       8,318

    Adjusted operating income     $20,349     $16,746     $62,200     $48,024
    Adjusted operating income
     margin                          13.3%       13.4%       14.0%       13.2%



                              Colfax Corporation
                            Sales and Order Growth
                            (amounts in millions)
                                 (unaudited)


                                                Sales            Orders
                                              $       %        $       %

    Three Months Ended September 28, 2007  $125.4           $153.6

    Components of Growth:
    Existing Businesses                      17.9   14.3%      8.7    5.7%
    Acquisitions                              1.2    1.0%      2.2    1.4%
    Foreign Currency Translation              9.0    7.1%      9.3    6.0%

      Total Growth                           28.1   22.4%     20.2   13.2%


    Three Months Ended September 26, 2008  $153.5           $173.8

                                               Sales            Orders
                                             $       %        $       %

    Nine Months Ended September 28, 2007   $362.6           $425.0

    Components of Growth:
    Existing Businesses                      42.7   11.8%     66.8   15.7%
    Acquisitions                              4.7    1.3%      8.6    2.0%
    Foreign Currency Translation             35.5    9.8%     42.5   10.0%

      Total Growth                           82.9   22.9%    117.9   27.7%

    Nine Months Ended September 26, 2008   $445.5           $542.9


SOURCE Colfax Corporation

http://www.colfaxcorp.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX